Nasdaq:GRCE
Grace Therapeutics, Inc.
Grace Therapeutics is a clinical-stage biopharma company developing gene-editing therapies for severe genetic diseases like cystic fibrosis.
Key Metrics
Investment Thesis
Bull Case
Investors might buy this stock due to the transformative potential of its gene-editing platform which could deliver one-time curative therapies for cystic fibrosis and other rare diseases. The company's low current liabilities relative to assets suggest a manageable balance sheet structure that could support multiple years of development before needing dilutive financing. If any clinical candidates achieve FDA approval, the resulting revenue upside from a blockbuster drug could be substantial given the unmet medical need in the genetic disease space.
Bear Case
The stock is risky because the company has never generated commercial revenue and carries a massive accumulated deficit of over $220 million that must be funded indefinitely. A failure in any upcoming clinical trial would likely wipe out significant equity value, as there is no cash flow generation to buffer against R&D failures. The total absence of profit before tax and negative net income trends indicate that the business model relies on perpetual capital infusion rather than organic growth.
About Grace Therapeutics, Inc.
Grace Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe genetic diseases, primarily cystic fibrosis, in the United States. The company leverages its proprietary research platforms to advance gene-editing technologies aimed at delivering curative treatments to patients with life-threatening conditions. With no current product revenue but significant assets under management, the firm relies heavily on financing activities to fund its extensive research and development pipeline.
Analysis
Management Discussion
Grace Therapeutics reported a net loss of $9.6 million in 2025, reflecting continued heavy investment in its research and development efforts totaling $16.7 million in operating expenses. Despite the negative operating profit, the company maintained a healthy cash position with $22.1 million in cash and equivalents, supported by recent financing inflows of $14.0 million which helped offset operational cash outflows. The reduction in losses from prior years suggests improving operational efficiency, though the company remains in a pre-revenue stage typical for early-stage biotech firms.
Industry Overview
The biopharmaceutical industry for rare genetic diseases is highly competitive and capital intensive, characterized by long development timelines and high failure rates in clinical trials. Companies in this space often rely on strategic partnerships or public financing to sustain operations until product milestones are achieved. Regulatory environments remain strict regarding gene-editing technologies, requiring extensive safety data to secure approval from agencies like the FDA.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | — | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | — | $0 | $0 |
| Operating Expenses | — | $12.9M | $16.7M |
| Operating Income | $-52.2M | $-12.9M | $-16.7M |
| R&D | $10.0M | $4.7M | $9.5M |
| G&A | $7.6M | $6.4M | $7.2M |
| Marketing | $661.0K | $252.0K | — |
| Stock-Based Comp | $1.8M | $913.0K | $730.0K |
| Depreciation | $124.0K | $11.0K | $7.0K |
| Other OpEx | — | $1.5M | $0 |
| Non-Operating Income | $184.0K | $-1.8M | $3.9M |
| Interest Income | $246.0K | $911.0K | $711.0K |
| Pre-Tax Income | $-52.0M | $-14.7M | $-12.8M |
| Income Tax | $-9.5M | $-1.8M | $-3.2M |
| Continuing Ops | $-42.4M | $-12.9M | $-9.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-42.4M | $-12.9M | $-9.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-42.4M | $-12.9M | $-9.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $29.3M | $24.0M | $22.7M |
| Cash & Equivalents | $27.9M | $23.0M | $22.1M |
| Marketable Securities | $15.0K | $0 | — |
| Accounts Receivable | $802.0K | $722.0K | — |
| Other Current Assets | $598.0K | $283.0K | $579.0K |
| Long-Term Assets | $49.8M | $49.3M | $49.3M |
| PP&E (Net) | $12.2M | $24.0K | $15.0K |
| Intangibles | $41.1M | $41.1M | $41.1M |
| Goodwill | $8.1M | $8.1M | $8.1M |
| Operating Leases | $463.0K | $0 | — |
| Other LT Assets | $-12.1M | $0 | $0 |
| Total Assets | $79.1M | $73.3M | $72.0M |
| Current Liabilities | $3.4M | $1.7M | $1.9M |
| Current Leases | $75.0K | $0 | — |
| Other Current Liab | $2.4M | $1.5M | — |
| Long-Term Liabilities | $7.8M | $9.9M | $3.5M |
| LT Operating Leases | $410.0K | $0 | — |
| Other LT Liab | $7.3M | $9.9M | — |
| Total Liabilities | $11.2M | $11.6M | $5.4M |
| Shareholders' Equity | $68.0M | $61.7M | $66.6M |
| Paid-In Capital | $14.0M | $17.9M | $293.3M |
| Retained Earnings | $-198.3M | $-211.1M | $-220.7M |
| AOCI | $-6.0M | $-6.0M | $-6.0M |
| Total L&E | $79.1M | $73.3M | $72.0M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-42.4M | $-12.9M | $-9.6M |
| Non-Cash Adjustments | $27.3M | $2.6M | $-4.8M |
| Working Capital Changes | $-822.0K | $-2.1M | $-510.0K |
| Cash from Operations | $-15.9M | $-12.3M | $-14.9M |
| Cash from Investing | $13.2M | $104.0K | $0 |
| Cash from Financing | $304.0K | $7.4M | $14.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-2.5M | $-4.9M | $-872.0K |
| Beginning Cash | $30.3M | $27.9M | $23.0M |
| Ending Cash | $27.9M | $23.0M | $22.1M |
Frequently Asked Questions
How does Grace Therapeutics, Inc. make money?
The company operates primarily through a single strategic segment focused on drug discovery and development, specifically targeting rare diseases such as cystic fibrosis. Revenue generation is currently in the pre-commercial phase, with all financial activity directed toward research and development expenditures and capitalization of intangible assets rather than commercial sales.
What are the main risks for GRCE?
The company faces significant commercialization risk as it has no current revenue stream and relies entirely on external capital markets to fund operations. There is a high degree of uncertainty regarding the success of its clinical trials, which could result in total loss of invested R&D funds if therapies fail to demonstrate efficacy or safety. The biopharmaceutical sector is characterized by intense competition for talent and resources, while regulatory approval processes can be unpredictable and lengthy. Additionally, the company's substantial accumulated deficit and ongoing cash burn indicate a vulnerability to funding gaps if investor sentiment shifts.
What is GRCE's competitive advantage?
The company possesses specialized expertise in CRISPR-based gene editing technologies tailored for difficult-to-treat genetic disorders. Grace holds a robust pipeline of clinical candidates that could offer transformative, one-time curative therapies with the potential for superior long-term value compared to existing chronic care models. Strong cash reserves and strategic financing inflows provide necessary runway to advance multiple high-value programs through pivotal clinical trials.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.